Overview

Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy of the effective drugs in a alternating chemotherapy schedules in pretreated patients with mCRC, who have received all effective drugs.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital of Crete
Treatments:
Bevacizumab
Camptothecin
Cetuximab
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin